Biblio
Unfavorable transcriptome profiles and social disadvantage in hematopoietic cell transplantation: a CIBMTR analysis. Blood Adv. 2023.
Severity of Chronic Graft-versus-Host Disease and Late Effects Following Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancy. Transplant Cell Ther. 2023.
Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2020.
Predictors of lost to follow-up among pediatric and adult hematopoietic cell transplant survivors: A report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2019.
Potent and uniform fetal hemoglobin induction via base editing. Nat Genet. 2023.
No impact of CD34 cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma. Bone Marrow Transplant. 2023.
Limitations of mouse models for sickle cell disease conferred by their human globin transgene configurations. Dis Model Mech. 2022;15(6).
. Impact of Public Reporting of Center-Specific Survival Analysis Scores on Patient Volumes at Hematopoietic Cell Transplant Centers. Transplant Cell Ther. 2023.
The impact of pre-apheresis Health Related Quality of Life on peripheral blood progenitor cell yield and donor's health and outcome: Secondary analysis of Patient-Reported Outcome Data from the RDSafe and BMT CTN 0201 Clinical Trials. Transplant Cell Ther. 2022.
Hematopoietic cell transplantation and gene therapy for Diamond-Blackfan anemia: state of the art and science. Front Oncol. 2023;13:1236038.
. Genome editing of HBG1 and HBG2 to induce fetal hemoglobin. Blood Adv. 2019;3(21):3379-3392.
Exagamglogene Autotemcel for Severe Sickle Cell Disease. N Engl J Med. 2024.
ERS/EBMT clinical practice guideline on treatment of pulmonary chronic graft--host disease in adults. Eur Respir J. 2024.
Engineering the best transplant outcome for high-risk acute myeloid leukemia: the donor, the graft and beyond. Cytotherapy. 2023.
Early immune reconstitution as predictor for outcomes after allogeneic hematopoietic cell transplant; a tri-institutional analysis. Cytotherapy. 2023.
Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell disease. Blood Adv. 2021;5(9):2403-2411.
Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP/EBMT study. Bone Marrow Transplant. 2024.
CRISPR-Cas9 Editing of the and Promoters to Treat Sickle Cell Disease. N Engl J Med. 2023;389(9):820-832.
Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Haematopoietic Stem Cell Transplant Recipients: A Cohort Study. Transplant Cell Ther. 2022.
Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. Lancet Haematol. 2021.